- $3.61bn
- $3.17bn
- $517.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 42.58 | ||
| PEG Ratio (f) | 189.08 | ||
| EPS Growth (f) | 0.23% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.68 | ||
| Price to Tang. Book | 7.34 | ||
| Price to Free Cashflow | 23.21 | ||
| Price to Sales | 6.66 | ||
| EV to EBITDA | 31.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.62% | ||
| Return on Equity | 6.93% | ||
| Operating Margin | 14.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 219.51 | 296.54 | 361.05 | 445.76 | 517.14 | 586.1 | 654.94 | 34.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +206.71 | -2.9 | +5.29 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Veracyte, Inc. is a global diagnostics company. It enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA laboratories in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Directors
- Bonnie Anderson CHM (63)
- Marc Stapley CEO (51)
- Rebecca Chambers CFO (43)
- Tina Nova CEX (67)
- Robert Brainin EVP (50)
- Bill Zondler SVP
- Beverly Alley CAO (58)
- Giulia Kennedy CSO (61)
- John Bishop LED (76)
- Muna Bhanji IND (58)
- Frederick Cohen IND (64)
- Karin Eastham IND (71)
- Robert Epstein IND (66)
- Kevin Gordon IND (58)
- Jens Holstein IND (57)
- Evan Jones IND (64)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- August 15th, 2006
- Public Since
- October 30th, 2013
- No. of Shareholders
- 15
- No. of Employees
- 755
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 79,792,647
- Address
- 6000 Shoreline Court, Suite 300, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.veracyte.com/
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Upcoming Events for VCYT
Veracyte Inc at Jefferies Global Healthcare Conference in New York
Veracyte Inc Annual Shareholders Meeting
Veracyte Inc Annual Shareholders Meeting
Q2 2026 Veracyte Inc Earnings Release
Q3 2026 Veracyte Inc Earnings Release
Similar to VCYT
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Veracyte share price?
As of Today at 05:58 UTC, shares in Veracyte are trading at $45.19. This share price information is delayed by 15 minutes.
How has the Veracyte share price performed this year?
Shares in Veracyte last closed at $45.19 and the price had moved by +63.67% over the past 365 days. In terms of relative price strength the Veracyte share price has outperformed the S&P500 Index by +28.42% over the past year.
What are the analyst and broker recommendations for Veracyte?
The overall consensus recommendation for Veracyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Veracyte dividend yield?
Veracyte does not currently pay a dividend.
Does Veracyte pay a dividend?
Veracyte does not currently pay a dividend.
When does Veracyte next pay dividends?
Veracyte does not currently pay a dividend.
How do I buy Veracyte shares?
To buy shares in Veracyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Veracyte?
As of the previous close price of $45.19, shares in Veracyte had a market capitalisation of $3.61bn.
Where are Veracyte shares listed?
Here are the trading details for Veracyte:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VCYT
What kind of share is Veracyte?
Based on an overall assessment of its quality, value and momentum Veracyte is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Veracyte share price forecast for 2026?
The analyst consensus target price for shares in Veracyte is $47.82. That is 5.82% above the last closing price of $45.19.
Analysts covering Veracyte currently have a consensus Earnings Per Share (EPS) forecast of $1.04 for the next financial year.
Find out moreWhat is the trend in the Veracyte share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Veracyte. Over the past six months, its share price has underperformed the S&P500 Index by -7.53%.
As of the last closing price of $45.19, shares in Veracyte were trading +23.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Veracyte PE Ratio?
The Veracyte PE ratio based on its reported earnings over the past 12 months is 42.58. The shares last closed at $45.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Veracyte?
Veracyte's management team is headed by:
- Bonnie Anderson - CHM
- Marc Stapley - CEO
- Rebecca Chambers - CFO
- Tina Nova - CEX
- Robert Brainin - EVP
- Bill Zondler - SVP
- Beverly Alley - CAO
- Giulia Kennedy - CSO
- John Bishop - LED
- Muna Bhanji - IND
- Frederick Cohen - IND
- Karin Eastham - IND
- Robert Epstein - IND
- Kevin Gordon - IND
- Jens Holstein - IND
- Evan Jones - IND